Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21110975 | 1.00 | MMP2 (0.35) | MMP2ANPEP | |
| SCHEMBL13288149 | 0.82 | MMP2 (0.36) | MMP2ANPEP | |
| SCHEMBL15819175 | 0.82 | ATM (0.40) | — | |
| SCHEMBL26615005 | 0.82 | MMP2 (0.36) | MMP2ANPEP | |
| SCHEMBL376608 | 0.82 | MMP2 (0.36) | MMP2ANPEP | |
| SCHEMBL21111019 | 0.82 | MMP2 (0.36) | MMP2ANPEP | |
| SCHEMBL20554147 | 0.82 | ATM (0.40) | — | |
| SCHEMBL20973171 | 0.82 | ATM (0.40) | — | |
| SCHEMBL28995810 | 0.82 | ATM (0.40) | — | |
| SCHEMBL22557213 | 0.81 | MMP2 (0.35) | MMP2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-09-28 | — | — | US | disclosed |
| EP-4025573-A1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2022-07-13 | — | — | EP | disclosed |
| CN-114341133-A | Substituted cyanopyrrolidines with USP30 inhibitor activity | 特殊治疗有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2021043870-A1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2021-03-11 | — | — | WO | disclosed |
| WO-2020212350-A1 | SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303547-A1 | N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | USP30, USP1, USP47 | MMP2 2363/4885ANPEP 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.